BIONET Therapeutics Corp.
TTPEX:780837.75
TWD
0.00
(0.00%)
BIONET Therapeutics Corp.
TPEX:7808
(Taipei Exchange)
Recent
price
37.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- BIONET Therapeutics Corp. is a Taiwan-based biotechnology company primarily engaged in the research, development, manufacturing, and commercialization of cell-derived therapeutics, exosome-based pharmaceuticals, and regenerative medicine solutions. The company operates through core segments encompassing Exosome and Cell Therapeutics, Regenerative CDMO Services, and Bio-Aesthetic Ingredients. Its comprehensive product and service portfolio includes proprietary exosome formulations and biopharmaceuticals targeted at ophthalmic conditions, pulmonary inflammation, and tissue repair; Contract Development and Manufacturing Organization (CDMO) services offering cell culture expansion, exosome purification, analytical testing, quality control, and regulatory compliance under Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards; high-purity exosome raw materials, stem cell conditioned media, and bioactive ingredients for dermatology, anti-aging cosmetics, and medical aesthetics; and AI-enabled bioinformatics platforms for cellular target identification, secretome profiling, and drug discovery. Founded in 2022 as a specialized biopharmaceutical subsidiary of BIONET Corp. and headquartered in Taipei, Taiwan, the company caters to biotechnology developers, clinical research centers, hospital systems, and cosmetic manufacturers across Taiwan, the Asia-Pacific region, and North America. Recent major corporate developments include the company's listing on the Emerging Stock Board of the Taipei Exchange (TPEX: 7808); the acceleration of clinical-stage exosome drug pipeline candidates for dry eye syndrome, corneal repair, and acute respiratory distress syndrome under Taiwan's Regenerative Medicine Act framework; the expansion of international CDMO alliances and supply agreements across Japan, the United States, and Southeast Asia; and the launch of next-generation artificial intelligence-assisted exosome analysis platforms to optimize therapeutic formulation development.